Ashley Plant-Fox

Sep 20, 2023 | nejm.org | Eric Bouffet |Jordan Hansford |Maria Luisa Garrè |Ashley Plant-Fox

September 21, 2023N Engl J Med 2023; 389:1108-1120 DOI: 10.1056/NEJMoa2303815 AbstractDetection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy.